Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Диагностическая ценность определения галектина-3 – нового биомаркера хронической сердечной недостаточности
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье приводится обзор результатов исследований, в которых производилось определение галектина-3 в качестве биомаркера хронической сердечной недостаточности. Также приведены данные экспериментальных исследований по оценке галектина-3 в аспекте сердечной недостаточности в условиях in vitro и in vivo.
Ключевые слова: биомаркер, сердечно-сосудистые заболевания, мониторинг эффективности терапии, прогноз заболевания, стратификация риска.
Ключевые слова: биомаркер, сердечно-сосудистые заболевания, мониторинг эффективности терапии, прогноз заболевания, стратификация риска.
________________________________________________
The review summarizes the results of clinical trials in which galectin-3 was assessed as biomarker of heart failure. In addition, most relevant information on galectin-3 received in in vitro and in vivo research is given with respect of heart failure.
Key words: biomarker, cardiovascular disease, therapy monitoring, prediction of outcome, patient stratification.
Полный текст
Список литературы
1. Агеев Ф.Т., Арутюнов Г.П. Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа, 2010.
2. Ho JM et al. Galectin-3, a marker of cardiac fibrosis, predicts incidence heart failure in the community. JACC 2012; 60 (14):1249–56.
3. Максимов М.Л. Влияние кардиоселективного бета-блокатора небиволола на глобальную и локальную сократимость миокарда у больных ишемической болезнью сердца, осложненной хронической сердечной недостаточностью. Автореф. дис. ... канд. мед. наук. М., 2004.
4. Агеев Ф.Т., Азизова А.Г. Галектин-3 – новый биохимический маркер сердечной недостаточности. Сердечная недостаточность. 2011; 12 (2).
5. Драпкина О.М., Дуболазова Ю.В. Применение биологических маркеров в диагностике диастолической сердечной недостаточности. Сердечная недостаточность. 2011; 12 (6).
6. Kramer F. Galectin-3: clinical utility and prognostic value in patients with heart failure. Reas Rep Clin Cardiology 2013; 4: 13–2.
7. Kim H, Lee J et al. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 2007; 31 (7): 655–2.
8. Ochieng J et al. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun 1998: 246 (3): 788–91.
9. Karlsson A et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology 2009; 19 (1): 16–20.
10. Sharma UC et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110 (19): 3121–8.
11. Shroen B, Heymans S et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res 2004; 95 (5): 515–22.
12. Henderson NC et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006; 103 (13): 5060–5.
13. Liu YH et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009; 296 (2): H404–H412.
14. Calvier L et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Atheroscler Thromb Vasc Biol 2013; 33 (1): 67–75.
15. de Boer RA et al. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010; 7 (1): 1–8.
16. van Kimmenade RR et al. Utility of aminoterminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48 (6): 1217–24.
17. Дуболазова Ю.В. Оценка клинического течения хронической сердечной недостаточности с сохраненной фракцией выброса. Автореф. дис. ... канд. мед. наук. М., 2012.
18. Gullestad L et al. CORONA Study group. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 2012; 33 (18): 2290–6.
19. Kjekhus J et al. CORONA group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357 (22): 2248–61.
20. Cohn JN et al. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Eng J Med 2001; 345 (23): 1667–75.
21. Anand IS et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J of Heart Failure Epub 2013, Jan 4.
22. Milting H et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008; 27 (6): 589–96.
23. Erkilet G et al. Plasma galectin-3 is increased in terminal heart failure patients and is elevated in patients surviving mechanical circulatory support. J Heart Lung Transplant 2010; 29 (2): S65.
24. Lopez-Andrez N et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction and dyssynchrony: insights from CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012; 14 (1).
25. Lok DJ et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. Epub August 12, 2012
26. Felker GM et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012; 5 (1): 72–8.
27. Lok DJ et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from DEAL-HF study. Clin Res Cardiol 2010; 99 (5): 323–28.
28. Erkilet G et al. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. J Heart Lung Transplant 2013; 32 (2): 221–30.
29. de Boer RA et al. Predictive values of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43 (1): 60–8.
30. Shah RV et al. Galectin-3, cardiac structure and function and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010; 12 (8): 826–32.
31. de Boer RA et al. The fibrosis marker galectin-3 and outcome in general population. J Intern Med 2012; 272 (1): 55–64.
32. Biomarker Definitions Working Group. Biomarkers and surrogate end-points: preffered definitions and conceptual framework. Clin Pharmacol Ther 2001; 69 (3): 89–95.
2. Ho JM et al. Galectin-3, a marker of cardiac fibrosis, predicts incidence heart failure in the community. JACC 2012; 60 (14):1249–56.
3. Максимов М.Л. Влияние кардиоселективного бета-блокатора небиволола на глобальную и локальную сократимость миокарда у больных ишемической болезнью сердца, осложненной хронической сердечной недостаточностью. Автореф. дис. ... канд. мед. наук. М., 2004.
4. Агеев Ф.Т., Азизова А.Г. Галектин-3 – новый биохимический маркер сердечной недостаточности. Сердечная недостаточность. 2011; 12 (2).
5. Драпкина О.М., Дуболазова Ю.В. Применение биологических маркеров в диагностике диастолической сердечной недостаточности. Сердечная недостаточность. 2011; 12 (6).
6. Kramer F. Galectin-3: clinical utility and prognostic value in patients with heart failure. Reas Rep Clin Cardiology 2013; 4: 13–2.
7. Kim H, Lee J et al. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 2007; 31 (7): 655–2.
8. Ochieng J et al. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun 1998: 246 (3): 788–91.
9. Karlsson A et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology 2009; 19 (1): 16–20.
10. Sharma UC et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110 (19): 3121–8.
11. Shroen B, Heymans S et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res 2004; 95 (5): 515–22.
12. Henderson NC et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006; 103 (13): 5060–5.
13. Liu YH et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009; 296 (2): H404–H412.
14. Calvier L et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Atheroscler Thromb Vasc Biol 2013; 33 (1): 67–75.
15. de Boer RA et al. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010; 7 (1): 1–8.
16. van Kimmenade RR et al. Utility of aminoterminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48 (6): 1217–24.
17. Дуболазова Ю.В. Оценка клинического течения хронической сердечной недостаточности с сохраненной фракцией выброса. Автореф. дис. ... канд. мед. наук. М., 2012.
18. Gullestad L et al. CORONA Study group. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 2012; 33 (18): 2290–6.
19. Kjekhus J et al. CORONA group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357 (22): 2248–61.
20. Cohn JN et al. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Eng J Med 2001; 345 (23): 1667–75.
21. Anand IS et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J of Heart Failure Epub 2013, Jan 4.
22. Milting H et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008; 27 (6): 589–96.
23. Erkilet G et al. Plasma galectin-3 is increased in terminal heart failure patients and is elevated in patients surviving mechanical circulatory support. J Heart Lung Transplant 2010; 29 (2): S65.
24. Lopez-Andrez N et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction and dyssynchrony: insights from CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012; 14 (1).
25. Lok DJ et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. Epub August 12, 2012
26. Felker GM et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012; 5 (1): 72–8.
27. Lok DJ et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from DEAL-HF study. Clin Res Cardiol 2010; 99 (5): 323–28.
28. Erkilet G et al. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. J Heart Lung Transplant 2013; 32 (2): 221–30.
29. de Boer RA et al. Predictive values of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43 (1): 60–8.
30. Shah RV et al. Galectin-3, cardiac structure and function and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010; 12 (8): 826–32.
31. de Boer RA et al. The fibrosis marker galectin-3 and outcome in general population. J Intern Med 2012; 272 (1): 55–64.
32. Biomarker Definitions Working Group. Biomarkers and surrogate end-points: preffered definitions and conceptual framework. Clin Pharmacol Ther 2001; 69 (3): 89–95.
Авторы
К.А.Гямджян, М.Л.Максимов
Кафедра клинической фармакологии и пропедевтики внутренних болезней ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
Кафедра клинической фармакологии и пропедевтики внутренних болезней ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
________________________________________________
K.A.Gyamdzhyan, M.L.Maksimov
Department of Clinical Pharmacology and Internal Propaedeutic Medicine, Sechenov first medical university
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.